Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.

@article{Niho2013CombinationCW,
  title={Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.},
  author={Seiji Niho and Hirotsugu Kenmotsu and Ikuo Sekine and Genichiro Ishii and Yuichi Ishikawa and Masayuki Noguchi and Fumihiro Oshita and Shun-ichi j. Watanabe and Ryu Nakajima and Hirohito Tada and Kanji Nagai},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2013},
  volume={8 7},
  pages={
          980-4
        }
}
INTRODUCTION We conducted a phase II study of combination chemotherapy with irinotecan (CPT) and cisplatin (CDDP) in patients with advanced large-cell neuroendocrine carcinoma (LCNEC) of the lung. METHODS Patients received irinotecan (60 mg/m², days 1, 8, and 15) and cisplatin (60 mg/m², day 1) every 4 weeks for up to four cycles. The primary endpoint was the response rate. Expected and threshold values for the primary endpoint were 50% and 30%. RESULTS Forty-four patients were enrolled… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 39 CITATIONS

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Jarushka Naidoo, Maria L Santos-Zabala, +15 authors Maria C Pietanza
  • Clinical lung cancer
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Advances on systemic treatment for lung neuroendocrine neoplasms.

  • Annals of translational medicine
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate

Roberto A. Escala Cornejo, Paloma García-Talavera, +4 authors Juan J. Cruz Hernández
  • Annals of Nuclear Medicine
  • 2018
VIEW 1 EXCERPT
CITES METHODS